Survival outcomes of liposomal irinotecan in patients with advanced pancreatic adenocarcinoma previously treated with conventional irinotecan-based chemotherapy: A single-institution experience

被引：0
|
作者：
Gupta, Amol [1 ]
Kamel, Ihab R. [1 ]
Laheru, Dan [1 ]
机构：
[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16260
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study
    Gupta, Amol
    De Jesus-Acosta, Ana
    Zheng, Lei
    Lee, Valerie
    Kamel, Ihab
    Le, Dung
    Pishvaian, Michael
    Laheru, Daniel
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [2] Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
    Bang, Kyunghye
    Cheon, Jaekyung
    Jeong, Jae Ho
    Im, Hyeon-Su
    Kim, Kyu-pyo
    Ryoo, Baek-Yeol
    Yoo, Changhoon
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [3] Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience
    Tossey, Justin C.
    Reardon, Joshua
    VanDeusen, Jeffrey B.
    Noonan, Anne M.
    Porter, Kyle
    Arango, Matthew J.
    MEDICAL ONCOLOGY, 2019, 36 (10)
  • [4] Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience
    Justin C. Tossey
    Joshua Reardon
    Jeffrey B. VanDeusen
    Anne M. Noonan
    Kyle Porter
    Matthew J. Arango
    Medical Oncology, 2019, 36
  • [5] Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-world evidence
    Gupta, Amol
    De Jesus-Acosta, Ana
    Le, Dung
    Pishvaian, Michael
    Zaidi, Neeha
    Zheng, Lei
    Laheru, Daniel
    CANCER, 2024,
  • [6] Real-world clinical outcomes of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens: Impact of prior irinotecan (IRI) exposure
    Yu, Kenneth H.
    Cockrum, Paul
    Surinach, Andy
    Lamarre, Neil
    Wang, Shu
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [7] Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
    Yu, Kenneth H.
    Hendifar, Andrew E.
    Alese, Olatunji B.
    Draper, Amber
    Abdelrahim, Maen
    Burns, Ethan
    Khan, Gazala
    Cockrum, Paul
    Bhak, Rachel H.
    Nguyen, Catherine
    DerSarkissian, Maral
    Duh, Mei Sheng
    Bahary, Nathan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [8] REAL-WORLD CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH METASTATIC DUCTAL ADENOCARCINOMA (MPDAC) TREATED WITH LIPOSOMAL IRINOTECAN-BASED REGIMENS BY RACE
    Kim, G. P.
    Cockrum, P.
    Lamarre, N.
    Surinach, A.
    VALUE IN HEALTH, 2021, 24 : S23 - S23
  • [9] Understanding extended duration of therapy (DOT) among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens
    Mokrzecky, Cheryl
    Cockrum, Paul
    Surinach, Andy
    Becerra, Carlos Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [10] Real-world progression outcomes among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States
    Kim, G.
    Cockrum, P.
    Surinach, A.
    Wang, S.
    Lamarre, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S1092 - S1093
12345